INTRODUCTION: Brachytherapy may be complicated by serious obstructive voiding symptoms (OVS). Only conservative treatment options are available in the first 6 months after brachytherapy. We evaluated safety, efficacy and patient tolerance of the Memokath prostatic stent (MPS). MATERIAL AND METHODS: A MPS was placed in 10 patients with OVS after brachytherapy. Evaluation included uroflowmetry, international prostate symptom score (IPSS), prostate volume and urethrocystoscopy before and 3 months after placement of the stent. RESULTS: Both the IPSS and uroflowmetry results significantly improved after stent insertion. The mean IPSS decreased from 29/5 to 11/1 and the mean Qmax from the uroflowmetry improved from 4.7 to 11.2 ml/s. The 5 patients who were catheter dependent voided spontaneously with a mean Qmax of 15 ml/s. Two stents migrated towards the bladder, and those patients needed a second stent which was placed without complications. Removal of the stent was easy to perform. Adverse effects were minor with perineal pain and irritative voiding symptoms occurring in 5 patients mainly in the first weeks after insertion. This did not negatively influence quality of life and all patients were more satisfied with the stent than without. CONCLUSIONS: The MPS provides a safe, effective, and completely reversible treatment for patients with OVS after brachytherapy and was well tolerated.
INTRODUCTION: Brachytherapy may be complicated by serious obstructive voiding symptoms (OVS). Only conservative treatment options are available in the first 6 months after brachytherapy. We evaluated safety, efficacy and patient tolerance of the Memokath prostatic stent (MPS). MATERIAL AND METHODS: A MPS was placed in 10 patients with OVS after brachytherapy. Evaluation included uroflowmetry, international prostate symptom score (IPSS), prostate volume and urethrocystoscopy before and 3 months after placement of the stent. RESULTS: Both the IPSS and uroflowmetry results significantly improved after stent insertion. The mean IPSS decreased from 29/5 to 11/1 and the mean Qmax from the uroflowmetry improved from 4.7 to 11.2 ml/s. The 5 patients who were catheter dependent voided spontaneously with a mean Qmax of 15 ml/s. Two stents migrated towards the bladder, and those patients needed a second stent which was placed without complications. Removal of the stent was easy to perform. Adverse effects were minor with perineal pain and irritative voiding symptoms occurring in 5 patients mainly in the first weeks after insertion. This did not negatively influence quality of life and all patients were more satisfied with the stent than without. CONCLUSIONS: The MPS provides a safe, effective, and completely reversible treatment for patients with OVS after brachytherapy and was well tolerated.
Authors: Marion P R Van Gellekom; Marinus A Moerland; Marco Van Vulpen; Harm K Wijrdeman; Jan J Battermann Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-20 Impact factor: 7.038
Authors: James N Armitage; Arash Rashidian; Paul J Cathcart; Mark Emberton; Jan H P van der Meulen Journal: BJU Int Date: 2006-07-28 Impact factor: 5.588
Authors: Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath Journal: Int J Radiat Oncol Biol Phys Date: 2004-01-01 Impact factor: 7.038
Authors: David B Bayne; Thomas W Gaither; Mohannad A Awad; Gregory P Murphy; E Charles Osterberg; Benjamin N Breyer Journal: Transl Androl Urol Date: 2017-04